Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy

Zhao, Xiao Ling; Yang, Keni; Zhao, Ruifang; Ji, Tianjiao; Wang, Xiuchao; Xiao, Yang; Zhang, Yinlong; Cheng, Keman; Liu, Shaoli; Hao, Jihui; Ren, He; Leong, Kam W.; Nie, Guangjun

doi:10.1016/j.biomaterials.2016.06.032

Cited by 219 publications

(173 citation statements)

References 53 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…The OXA-NPs were more effective than the free OXA at an equivalent dose, and both could cause ICD as measured by CRT exposure and the release of DAMPs: ATP and HMGB1. CRT exposure was detected after 10 hours of OXA-NP treatment, while HMGB1 and secreted ATP levels were highest 48 hours after treatment [35]. …”

Section: Type I Icd Inductionmentioning

confidence: 99%

“…After the incubation period of 24 hours, DCs were measured for maturation markers CD80 and CD83. Both the primary cells and DC 2.4 cell line, cultured in conditioned media from cancer cells treated with OXA-NPs, had increased maturation markers when compared to DCs exposed to untreated cell conditioned media [35]. Taken together, data from these studies indicate that ICD induction, across a range of cancer cell lines and using different type I ICD inducers, resulted in exposure of either membrane-bound or secreted DAMPs (or both), which led to phagocytosis of the dying cancer cells and the robust maturation of antigen-specific DCs.…”

Section: Type I Icd Inductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytokines in immunogenic cell death: Applications for cancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can efficiently eliminate cancer cells, long-term protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most effective ways to protect against cancers that recur and/or metastasize. Activated tumor specific cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drug-resistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the fight against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their effects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore different types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.

show abstract

Section: Type I Icd Inductionmentioning

confidence: 99%

Section: Type I Icd Inductionmentioning

confidence: 99%

Cytokines in immunogenic cell death: Applications for cancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A study by Zhao et al showed for example that delivery of oxaliplatin by PLGA nanocarriers [10] (NP-OXA) induced a stronger immune response both in vitro (in co-culture assays of stimulated DCs and T-cells) and in immunocompetent mice, compared to oxaliplatin alone (OXA). In particular, NP-OXA-treated mice showed a higher proportion of tumor infiltrated lymphocytes (TILs), higher IFN-γ expression and increased tumor shrinkage compared to OXA treatment alone [10]. These results show that encapsulation improved the drug immunogenicity by increasing ICD, thus leading to a more pronounced immune response.…”

Section: Immunomodulatory Drug Deliverymentioning

confidence: 99%

“…Interestingly, a novel approach combining delivery of both cytotoxic drugs and cytokines through nanoparticles is also being pursued. The rationale here is of a “two-hit” strike to cancer cells: a “first-hit” due to the drug cytotoxic effect leading to cell apoptosis, activation of APCs and subsequent triggering of an immune response, and a “second-hit” which improves and sustains such immune response through the cytokine/TLR agonist action [10]. An example of this approach is the administration of lipid-coated cisplatin nanoparticles (LPC) followed by CpG-encapsulated liposomes 1 day after in a melanoma mouse model.…”

Section: Immunomodulatory Drug Deliverymentioning

confidence: 99%

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

et al. 2017

View full text Add to dashboard Cite

BackgroundImmunotherapy consists of activating the patient’s immune system to fight cancer and has the great potential of preventing future relapses thanks to immunological memory. A great variety of strategies have emerged to harness the immune system against tumors, from the administration of immunomodulatory agents that activate immune cells, to therapeutic vaccines or infusion of previously activated cancer-specific T cells. However, despite great recent progress many difficulties still remain, which prevent the widespread use of immunotherapy. Some of these limitations include: systemic toxicity, weak immune cellular responses or persistence over time and most ultimately costly and time-consuming procedures.Main bodySynthetic and natural biomaterials hold great potential to address these hurdles providing biocompatible systems capable of targeted local delivery, co-delivery, and controlled and/or sustained release. In this review we discuss some of the bioengineered solutions and approaches developed so far and how biomaterials can be further implemented to help and shape the future of cancer immunotherapy.ConclusionThe bioengineering strategies here presented constitute a powerful toolkit to develop safe and successful novel cancer immunotherapies.

show abstract

“…In addition, together with ICD, combination therapy including checkpoint blockers has the high probability to achieve more efficient therapeutic effects in clinical settings [6]. In this effort, nanoparticle-based immunotherapeutic strategies for the treatment of cancer, serving as antigen/adjuvant delivery vehicles and their combinations with chemotherapeutics, could further facilitate the development of the field [8][9][10].…”

mentioning

confidence: 99%

Critical role of immunogenic cell death in cancer therapy

Xia

2017

Science Bulletin

View full text Add to dashboard Cite

Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy

Cited by 219 publications

References 53 publications

Cytokines in immunogenic cell death: Applications for cancer immunotherapy

Cytokines in immunogenic cell death: Applications for cancer immunotherapy

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Critical role of immunogenic cell death in cancer therapy

Contact Info

Product

Resources

About